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Introduction
Zoledronic acid (ZA) is a potent nitrogen-containing
bisphosphonate with a long skeletal half-life that is
administered annually by intravenous (IV) infusion. In the
Horizon trial, ZA significantly reduced the risk of vertebral
fracture by 70%, the risk of hip fracture by 40%, and the
risk of nonvertebral fracture by 20% [1]. ZA also reduced
the risk of clinical fracture by 35% and decreased mortality
by 28% after hip fracture in the Recurrent Fracture Trial
[2]. A combination of antifracture efficacy, low rate of
adverse events, and infrequent dosing make it a desirable
agent for the future.
Aims
Defining the duration of action of zoledronate and the
optimal dosing interval may help reduce the cost of an
effective therapy.
Methods
Andrew Grey performed a 3-year randomized placebo-
controlled trial of the effects on bone turnover and bone
mineral density (BMD) of a single infusion of 5 mg IV
zoledronate. Fifty postmenopausal women with osteoporo-
sis were randomized to either a single infusion of IV ZA or
placebo. The primary end points were bone turnover
markers such as β CTX (C telopeptide) and P1NP
(procollagen type I N-terminal propeptide). Secondary end
points were BMD of the lumbar spine, total hip, and total
body. After 3 years, bone markers, serum β CTX, and
P1NP were 44% and 40% lower in the zoledronate group
(P<0.001 vs placebo for each marker). BMD was higher in
the zoledronate than in the placebo group by an average of
6.8% in the lumbar spine, 4.0% total hip, and 2.0% of total
body (P<0.001 for each skeletal site). Between-group
differences in makers of bone turnover and BMD were
stable from 12 to 36 months.
Discussion
The data demonstrate the antiresorptive effects of a single
5-mg IV dose of zoledronate was sustained for 3 years and
suggests we may wish to consider investigating the
antifracture efficacy of ZA in dosing intervals longer than
1 year. However, it is important to note that the Horizon
trial, which required IVonce yearly for 3 years, is the only
trial that has shown fracture efficacy as an end point in the
treatment of patients at risk for osteoporotic fracture.
A recent report by Black et al. [3] at the 2010 American
Society for Bone and Mineral Research Meeting in Toronto
of a 3-year extension of the Horizon trial addresses another
related issue, the possibility of a holiday after 3 years
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DOI 10.1007/s11914-010-0044-xtreatment. Black et al. [3] identified 1,233 patients in the
Horizon trial at year 3 who were randomized to either
continued infusions of IV ZA or placebo. BMD remained
constant at all sites in the 6-year ZA group, whereas there
was a slight drop in femoral neck BMD of about 1% in the
group that received 3 years of placebo injection after
3 years of ZA but the BMD remained well above
pretreatment levels.. Results for other sites of BMD were
similar. Biochemical markers remained constant in the
group receiving ZA for 6 years but rose slightly in the
group receiving placebo for 3 years. New morphometric
vertebral fractures were significantly lower in the group
receiving six ZA injections (RR=0.48, P=0.04), whereas
other categories of fractures including nonvertebral, hip,
and clinical vertebral were not different between study
groups.
Conclusions
The data demonstrate that the antiresorptive effect of IV ZA
is sustained for 3 years. Future studies of different dosing
intervals may be considered. However, for now we do
know that once-yearly IV ZA for 3 years is effective in
reducing fracture risk.
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